HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia

Owing to the recent emergence of drug resistance to Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic leukemia (CLL) treatment, it is crucial to identify alternative therapeutic targets. Therefore, we aimed to identify therapeutic options for CLL besides BTK. We identified that HIF1A...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Wancheng, Liang, Daomiao, Wang, Peilong, Yin, Le, Zhang, Huifang, Xing, Cheng, Huang, Zineng, Wu, Yinghua, Li, Heng, Cheng, Zhao, Xiao, Xiaojuan, Liu, Jing, Wang, Zhihua, Peng, Hongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229586/
https://www.ncbi.nlm.nih.gov/pubmed/35745653
http://dx.doi.org/10.3390/ph15060734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229586/
https://www.ncbi.nlm.nih.gov/pubmed/35745653
http://dx.doi.org/10.3390/ph15060734

Ejemplares similares